| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 29, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 7:30 a.m. (ET)....
-
Jan 27, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that its Board of Directors declared a quarterly dividend of $0.125 per share, payable on March 17, 2015 to shareholders of record on...
-
Jan 22, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its second quarter fiscal year 2015 on Thursday, February 5, 2015 at approximately 8:00 a.m. (ET)....
-
Jan 12, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched its AB therapeutic equivalent testosterone gel 1.0%. The Food and Drug Administration (FDA) concluded previously that...
-
Jan 12, 2015
Perrigo Company plc (NYSE: PRGO; TASE), and Ferrara Candy Company, Inc. ("Ferrara"), announced today that Perrigo's Nutritionals division has signed a supply agreement with Ferrara to manufacture...
-
Jan 12, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched clobetasol propionate spray, 0.05%, the generic equivalent to Clobex® Spray, 0.05%. Perrigo was the first generic filer...
-
Jan 6, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman, President and CEO Joseph C. Papa will present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January...
-
Dec 2, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of the previously announced registered...
-
Dec 2, 2014
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for...
-
Nov 26, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the closing of Perrigo's previously announced...
-
Nov 24, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the registered public offering by...
-
Nov 24, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that the underwriters for Perrigo's previously...
-
Nov 24, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that Perrigo Finance plc, a finance subsidiary of...
-
Nov 24, 2014
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone undecanoate injection...
-
Nov 24, 2014
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic® Ointment 0.1% and 0.03%. Shipments to our...
-
Nov 20, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced the pricing of the registered public offering of...
-
Nov 20, 2014
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," today announced that it is commencing a registered public offering of...
-
Nov 6, 2014
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States....
-
Nov 6, 2014
Fiscal first quarter net sales increased to a first quarter record of $952 million. Fiscal first quarter adjusted net income increased 30% to a first quarter record of $188 million, with reported...
-
Nov 6, 2014- Accelerates Perrigo's stated strategy to expand internationally and leverage its existing product portfolio
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe,...
-
Nov 3, 2014
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on December 16, 2014 to shareholders of record on...
-
Oct 23, 2014
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it will release financial results for its first quarter fiscal year 2015 on Thursday, November 6, 2014 at approximately 8:00 a.m. (ET)....
-
Oct 14, 2014
Perrigo Animal Health, a division of Perrigo Company plc (NYSE: PRGO; TASE), is proud to announce that its Kansas City, Kansas, manufacturing facility has obtained Safety Quality Food (SQF) Code...
-
Oct 2, 2014
Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the expiration of its offer to exchange (the "Exchange...
-
Oct 1, 2014
Perrigo Company plc (NYSE: PRGO; TASE), a public limited company incorporated under the laws of Ireland (the "Company"), today announced the extension of its offer to exchange (the "Exchange...